Efloxate - Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 18:43, 2 September 2011 (Updating {{drugbox}} (changes to watched fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikiped). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 18:43, 2 September 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to watched fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikiped)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound

Efloxate
Clinical data

ATC code	C01DX13 (WHO)
Identifiers
IUPAC name ethyl 2-acetate
PubChem CID	8395
UNII	CZU6V3902K
CompTox Dashboard (EPA)	DTXSID3048736
ECHA InfoCard	100.003.929
Chemical and physical data
Formula	C₁₉H₁₆O₅
Molar mass	324.33 g/mol g·mol
(verify)

Efloxate is a vasodilator.

v t e Vasodilators used in cardiac diseases (C01D)
Nitrovasodilators	Nitroglycerin # Isosorbide dinitrate # Isosorbide mononitrate Itramin tosilate Linsidomine Molsidomine Nicorandil Pentaerythritol tetranitrate Propatylnitrate Tenitramine Trolnitrate
Quinolone vasodilators	Flosequinan
Others	Benziodarone Carbocromen Cinepazet Cloridarol Dilazep Efloxate Etafenone Gapicomine Heptaminol Hexobendine Imolamine Levosimendan Nesiritide Nicorandil Oxyfedrine Pimobendan Prenylamine Serelaxin Trapidil Vericiguat
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

Categories: